Abstract
In this chapter, we discuss the situation in countries with a national healthcare system and do not cover countries with private healthcare insurance or those where services are paid out of pocket. Very few countries can meet all the costs of modern medicine for all their citizens. The three consequences of the gap between the available resources and the costs of modern medicine are limited access to costly medical interventions, waiting times for diagnostic and therapeutic interventions, and list of priorities. From the ethical standpoint, it is essential that all three of these issues are openly discussed and agreed within a wide circle including medical professionals and representatives of the lay community. In case of lack of democratic agreement and of clear rules, access to medical care may depend on the social and/or economic position of an individual. In a society based on solidarity, such a situation is contrary to the ethical principle of justice and may be considered to be a form of corruption.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Originator (also original) drugs are those that have been granted marketing authorization on the basis of studies done by the manufacturer that prove the drug’s safety, quality, and efficacy. Once the originator drug loses patent protection, another manufacturer can make and market a generic drug with the same active substance. Generic drugs are typically not tested in additional clinical studies and can be significantly cheaper.
- 2.
In Slovenia, the physician can indicate one of the four levels of urgency when referring a patient to a specialist: urgent, very fast, fast, or regular.
- 3.
In the drug information leaflet, the manufacturer writes: “We currently do not have sufficient data based on which we could recommend the use of Remifentanil during labor or Caesarean section. Remifentanil is transported through the placental membrane; analogues of Remifentanil can cause respiratory depression in newborns.” English anesthesiologist Prof. Felicity Reynolds Spencer, a leading expert, wrote that Remifentanil is “worse than useless” for managing labor pain and in many respects harmful to the newborn (personal communication, January 2, 2016).
Reference
Calltorp J. Priority setting in health policy in Sweden and a comparison with Norway. Health Policy. 1999;50:1–22.
Suggested Reading
Ciapponi A, Lewin S, Herrera CA, Opiyo N, Pantoja T, Paulsen E, et al. Delivery arrangements for health systems in low-income countries: an overview of systematic reviews. Cochrane Database Syst Rev. 2017;9:CD011083. https://doi.org/10.1002/14651858.CD011083.pub2.
Cromwell I, Peacock SJ, Mitton C. ‘Real-world’ health care priority setting using explicit decision criteria: a systematic review of the literature. BMC Health Serv Res. 2015;15:164. https://doi.org/10.1186/s12913-015-0814-3.
Fischer T, Langanke M. Individualized medicine: ethical, economical and historical perspectives. Berlin: Springer; 2015. ISBN-13: 978-3319346984.
Gaitonde R, Oxman AD, Okebukola PO, Rada G. Interventions to reduce corruption in the health sector. Cochrane Database Syst Rev. 2016;8:CD008856. https://doi.org/10.1002/14651858.CD008856.pub2.
Goldberg DS. Public health ethics and the social determinants of health, Springer Briefs in Public Health. Berlin: Springer; 2017. ISBN: 978-3-319-51347-8.
Gu Y, Lancsar E, Ghijben P, Butler JR, Donaldson C. Attributes and weights in health care priority setting: a systematic review of what counts and to what extent. Soc Sci Med. 2015;146:41–52. https://doi.org/10.1016/j.socscimed.2015.10.005.
Jamison DT, Alwan A, Mock CN, Nugent R, Watkins D, Adeyi O, et al. Universal health coverage and intersectoral action for health: key messages from disease control priorities, 3rd edition. Lancet. 2018;391:1108–20. https://doi.org/10.1016/S0140-6736(17)32906-9.
Kagawa-Singer M, Dadia AV, Yu MC, Surbone A. Cancer, culture, and health disparities: time to chart a new course? CA Cancer J Clin. 2010;60:12–39. https://doi.org/10.3322/caac.20051.
Kakuk P, editor. Bioethics and biopolitics: theories, applications and connections, Advancing Global Bioethics. Berlin: Springer; 2017. ISBN: 978-3-319-66249-7.
Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc. 2015;90:500–4. https://doi.org/10.1016/j.mayocp.2015.01.014.
Knaul F, Horton S, Yerramilli P, Gelband H, Atun R. Financing cancer care in low-resource settings. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: disease control priorities, vol. Vol. 3. 3rd ed. Washington, DC: The International Bank for Reconstruction and Development/The World Bank; 2015.
Moses H 3rd, Matheson DH, Dorsey ER, George BP, Sadoff D, Yoshimura S. The anatomy of health care in the United States. JAMA. 2013;310:1947–63. https://doi.org/10.1001/jama.2013.281425.
Nass SJ, Madhavan G, Augustine NR, editors. Making medicines affordable: a national imperative. Washington, DC: National Academies Press; 2017.
Patel V, Parikh R, Nandraj S, Balasubramaniam P, Narayan K, Paul VK, Kumar AK, Chatterjee M, Reddy KS. Assuring health coverage for all in India. Lancet. 2015;386:2422–35. https://doi.org/10.1016/S0140-6736(15)00955-1.
Prainsack B, Buyx A. Solidarity in biomedicine and beyond. Cambridge: Cambridge University Press; 2017. ISBN-13: 978-1107074248.
ten Have H. Vulnerability: challenging bioethics. Abingdon: Routledge; 2016. ISBN-13: 978-1138652675.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zwitter, M. (2019). Limited Resources, Priorities, and Corruption. In: Medical Ethics in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-00719-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-00719-5_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00718-8
Online ISBN: 978-3-030-00719-5
eBook Packages: MedicineMedicine (R0)